Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01454804 · ClinicalTrials.gov registry record · Phase 1
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT01454804: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01454804 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01454804, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combinations of pazopanib and either lapatinib or trastuzumab that can be given to patients with advanced cancer. The safety of the drug combinations will also be studied. Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for tumor growth. This may prevent or slow the growth of cancer cells. Lapatinib is designed to prevent or slow down the growth of cancer cells by blocking 2 proteins on the surface of the cancer cell, which are HER 1 and HER 2 receptors. Trastuzumab is designed to prevent or slow down the growth of cancer cells by blocking proteins inside the cancer cell, called the Her2/neu receptor.
Interventions
- DRUG Pazopanib
- DRUG Lapatinib
- DRUG Trastuzumab (Herceptin®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01454804
The ClinicalTrials.gov registry entry for NCT01454804 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pazopanib is the first listed.
NCT01454804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01454804 about?
NCT01454804 is a clinical study titled "Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors". The goal of this clinical research study is to find the highest tolerable dose of the combinations of pazopanib and either lapatinib or trastuzumab that can be given to patients with advanced cancer. The safety of the drug combinations will also be studied. Pazopanib is designed to block the growth...
What is the current status of trial NCT01454804?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2011-10. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01454804?
The interventions under investigation include: Pazopanib (DRUG), Lapatinib (DRUG), Trastuzumab (Herceptin®) (DRUG).
Who is sponsoring clinical trial NCT01454804?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.